BeOne Medicines registers Phase 1 trial of BG-T0050 in DLBCL and other B-cell cancers
BeOne Medicines registered a first-in-human Phase 1 study of trispecific T-cell engager BG-T0050 in relapsed or refractory aggressive B-cell lymphomas, not yet recruiting.
This week's filing covers a single new trial registration for BeOne Medicines.
- BeOne Medicines registered NCT07881211, a Phase 1, open-label, dose escalation and expansion study of BG-T0050 in diffuse large B-cell lymphoma and other aggressive B-cell malignancies, with status listed as not yet recruiting and an estimated start date of November 30, 2026. The study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-T0050 in these patients.1 BG-T0050 is an antibody-based immunotherapy designed to bind both cancer cells and T-cells, bringing the T-cells close enough to help destroy the cancer cells.1 The trial plans to enroll an estimated 70 adult participants across multiple global sites, with primary completion estimated for October 31, 2029.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.